Does Aficamten Interact with Fluvoxamine?
CDI records a major classification for Aficamten and Fluvoxamine. The stored summary is: Strong CYP2C19 inhibitor that increases aficamten exposure, potentially increasing risk of heart failure due to systolic dysfunction. Dose reduction required. The mechanism involves cyp2c19 inhibition (strong); also weak to moderate cyp3a, weak cyp2c9, and weak cyp2d6 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP2C19 inhibition (strong); also weak to moderate CYP3A, weak CYP2C9, and weak CYP2D6 inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Aficamten and your doctor is considering prescribing Fluvoxamine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider